ReviewProgress in neurobiology2012
Neurodegeneration as an RNA disorder.
Review in Progress in neurobiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Prolonged Survival with Dieting for Improved Autophagy.Non-coding RNA · 2025Review
- Evaluating the causal association between microRNAs and amyotrophic lateral sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Review
- Role of primary aging hallmarks in Alzheimer´s disease.Theranostics · 2023Review
- Huntingtin and Other Neurodegeneration-Associated Proteins in the Development of Intracellular Pathologies: Potential Target Search for Therapeutic Intervention.International journal of molecular sciences · 2022Review
- Neuroprotective Effects and Therapeutic Potential of the Citrus Flavonoid Hesperetin in Neurodegenerative Diseases.Nutrients · 2022Review
- The Emerging Role of Long Non-Coding RNAs and MicroRNAs in Neurodegenerative Diseases: A Perspective of Machine Learning.Biomolecules · 2021Review
- MicroRNA delivery through nanoparticles.Journal of controlled release : official journal of the Controlled Release Society · 2019Review
- Upregulation of miR-200a and miR-204 in MPPMolecular genetics & genomic medicine · 2019Article
- MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2018Review
- Competing Endogenous RNA Regulations in Neurodegenerative Disorders: Current Challenges and Emerging Insights.Frontiers in molecular neuroscience · 2018Review
- Article
- Article
- Synergistic effects of particulate matter (PMToxicology research · 2017Article
- Advances in the characterization of RNA-binding proteins.Wiley interdisciplinary reviews. RNA · 2016Review
- Motor Dysfunctions and Neuropathology in Mouse Models of Spinocerebellar Ataxia Type 2: A Comprehensive Review.Frontiers in neuroscience · 2016Review
- miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2016Review
- Regulation of protein homeostasis in neurodegenerative diseases: the role of coding and non-coding genes.Cellular and molecular life sciences : CMLS · 2015Review
- Role of MicroRNA in Visceral Pain.Journal of neurogastroenterology and motility · 2015Article
- Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders.CNS & neurological disorders drug targets · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases constitute one of the single most important public health challenges of the coming decades, and yet we presently have only a limited understanding of the underlying genetic, cellular and molecular causes. As a result, no effective disease-modifying therapies are currently available, and no method exists to allow detection at early disease stages, and as a result diagnoses are only made decades after disease pathogenesis, by which time the majority of physical damage has already occurred. Since the sequencing of the human genome, we have come to appreciate that the transcriptional output of the human genome is extremely rich in non-protein coding RNAs (ncRNAs). This heterogeneous class of transcripts is widely expressed in the nervous system, and is likely to play many crucial roles in the development and functioning of this organ. Most exciting, evidence has recently been presented that ncRNAs play central, but hitherto unappreciated roles in neurodegenerative processes. Here, we review the diverse available evidence demonstrating involvement of ncRNAs in neurodegenerative diseases, and discuss their possible implications in the development of therapies and biomarkers for these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.